P2, N=2, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2029 --> Jul 2025 | Withdrawn --> Terminated | Trial primary completion date: Sep 2028 --> Jul 2025; The study is being closed early due to insufficient participant enrollment across study sites.

IFX + AZA for rapid induction remission and RIF+AZA for maintenance therapy in IBD.

P=N/A, N=300, Recruiting, Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University

P=N/A, N=30, Recruiting, Children's Hospital,Zhejiang University School of Medicine; Children's Hospital,Zhejiang University School of Medicine

Patients with high and low RF levels experienced similar clinical responses to CZP treatment, irrespective of previous inadequate responses or intolerance to TNFis. These findings expand previous observations, supporting CZP as an effective treatment for patients with RA who have high RF levels and prior inadequate responses to TNFis.

P3/4, N=120, Active, not recruiting, The Alfred Hospital | Recruiting --> Active, not recruiting

P2, N=42, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting

She achieved disease control after transitioning to secukinumab, an interleukin-17 inhibitor. This case highlights the importance of early monitoring for paradoxical reactions in patients with severe psoriasis after initiating tumor necrosis factor-alpha inhibitor therapy and the value of transitioning to an alternative biologic class for effective management.

In this prospective, randomized, open-label, single-center study, 76 children with non-systemic JIA in stable remission for ≥24 months on etanercept or adalimumab were enrolled. Early significant clinical response, absence of subclinical disease activity, and concomitant low-dose methotrexate therapy were key predictors of sustained drug-free remission. These findings may inform personalized strategies for biologic tapering in pediatric JIA.

P1, N=800, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

We previously reported a significant correlation between protein-protein hydrogen bond robustness and the stability of the CRBN-CK1α complex induced by the antimyeloma drug lenalidomide. In this work, we demonstrate that this relationship is not unique for that system but rather represents a reproducible physicochemical phenomenon underlying the mechanism of action of chemically diverse MGs, including additional IMiDs and Fusicoccin A. Our results shed light on a vaguely understood phenomenon and pave the way for the development of new computational methods that enable the rational discovery of molecular glues.

P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028